Bayer Leaps to invests €1.3bn externally
German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Avantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.
Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
XNK Therapeutics AB has secured a private placement of €12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
Data Management has been a hotbed for development and innovation, correlating primarily with
the changing digital landscape. Clinical trial management has been significantly impacted, with the
electronic data capture and GDPR-compliance-led industry now unrecognisable from the paper-document administration methods of the past. This development process extends beyond COVID-19 and has a
noticeable impact on clinical trials.
ADCs have huge potential in treating challenging diseases such as cancer. However, it is essential that all necessary equipment, steps, and precautions are in place to en¬sure their safe handling.
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Sino Biological, a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.